Expansion strategies for Vδ2 γδT cells in cancer immunotherapy: Activation, cytokines, and culture conditions

Table 3 Comparison of different N-aminobisphosphonates

Name	Food and Drug Administration approval	Water solubility	Relative potency1	Ref.
Zoledronate	Yes	4.17 mg/mL	10000 ×	Kondo et al[68], Ruggiero et al[69]
Pamidronate	Yes	50 mg/mL	100 ×	Ruggiero et al[69], Kunzmann et al[70]
Alendronate	Yes	20 mg/mL	1000 ×	Ruggiero et al[69]
Ibandronate	Yes	72 mg/mL	5000 ×	Ruggiero et al[69]
Risedronate	Yes	11 mg/mL	5000 ×	Ruggiero et al[69]
Minodronate	No	20 mg/mL2	10000 ×	Ohishi and Matsuyama[71]
Neridronate	No	5 mg/mL2	100 ×	Ruggiero et al[69]
Olpadronate	No	50 mg/mL2	1000 ×	Ruggiero et al[69]

¹Relative potency with etidronate (a first-generation bisphosphonate) as the reference compound.

²Special conditions may be needed for water solubility, e.g., ultrasonic treatment, heating, pH adjustment.